Relay Therapeutics, Inc. (RLAY) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | -1971.6% | -1800.6% |
| 2024 | 100.0% | -3722.1% | -3374.7% |
| 2023 | 100.0% | -1460.1% | -1338.7% |
| 2022 | 100.0% | -21670.9% | -21036.1% |
| 2021 | 100.0% | -12040.2% | -12012.9% |
Download Data
Export RLAY earnings history in CSV or JSON format
Free sign-in required to download data
Relay Therapeutics, Inc. (RLAY) Earnings Overview
As of February 28, 2026, Relay Therapeutics, Inc. (RLAY) reported trailing twelve-month net income of -$276M, reflecting +0.3% year-over-year growth. The company earned $-1.61 per diluted share over the past four quarters, with a net profit margin of -18.0%.
Looking at the long-term picture, RLAY's historical earnings data spans multiple years. The company achieved its highest annual net income of -$49M in fiscal 2018.
Relay Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), RLAY has comparable earnings metrics. Compare RLAY vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$276M | +18.1% | -$303M | $-1.61 | -1800.6% | -1971.6% |
| 2024 | -$338M | +1.2% | -$372M | $-2.36 | -3374.7% | -3722.1% |
| 2023 | -$342M | -17.7% | -$373M | $-2.79 | -1338.7% | -1460.1% |
| 2022 | -$291M | +20.2% | -$299M | $-2.59 | -21036.1% | -21670.9% |
| 2021 | -$364M | -594.3% | -$365M | $-3.82 | -12012.9% | -12040.2% |
| 2020 | -$52M | +21.2% | -$56M | $-2.56 | -63.4% | -67.5% |
| 2019 | -$67M | -36.3% | -$84M | $-15.53 | - | - |
| 2018 | -$49M | - | -$50M | $-19.63 | - | - |
See RLAY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLAY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RLAY vs AGIO
See how RLAY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RLAY growing earnings?
RLAY EPS of $-1.61 reflects slowing growth at +0.3%, below the 5-year CAGR of N/A. TTM net income is $-276M. Expansion rate has moderated.
What are RLAY's profit margins?
Relay Therapeutics, Inc. net margin is -18.0%, with operating margin at -19.7%. Below-average margins reflect competitive or cost pressures.
How consistent are RLAY's earnings?
RLAY earnings data spans 2018-2025. The current earnings trend is +0.3% YoY. Historical data enables comparison across business cycles.